PSIP1
PC4 and SFRS1-interacting protein
Also known as: DFS70, LEDGF, p52, p75, PSIP1_HUMAN, PSIP2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75475
- Gene
- PSIP1
- Ensembl
- ENSG00000164985
- Chromosome
- 9
- Canonical length
- 530 aa
- Protein class
- Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Enables DNA-binding transcription factor binding activity; chromatin binding activity; and transcription coactivator activity. Involved in mRNA 5'-splice site recognition and positive regulation of transcription by RNA polymerase II. Located in heterochromatin; nuclear periphery; and nucleoplasm. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
530 residues, UniProt reviewed canonical sequence.
>O75475|PSIP1
1 MTRDFKPGDL IFAKMKGYPH WPARVDEVPD GAVKPPTNKL PIFFFGTHET AFLGPKDIFP
61 YSENKEKYGK PNKRKGFNEG LWEIDNNPKV KFSSQQAATK QSNASSDVEV EEKETSVSKE
121 DTDHEEKASN EDVTKAVDIT TPKAARRGRK RKAEKQVETE EAGVVTTATA SVNLKVSPKR
181 GRPAATEVKI PKPRGRPKMV KQPCPSESDI ITEEDKSKKK GQEEKQPKKQ PKKDEEGQKE
241 EDKPRKEPDK KEGKKEVESK RKNLAKTGVT STSDSEEEGD DQEGEKKRKG GRNFQTAHRR
301 NMLKGQHEKE AADRKRKQEE QMETEQQNKD EGKKPEVKKV EKKRETSMDS RLQRIHAEIK
361 NSLKIDNLDV NRCIEALDEL ASLQVTMQQA QKHTEMITTL KKIRRFKVSQ VIMEKSTMLY
421 NKFKNMFLVG EGDSVITQVL NKSLAEQRQH EEANKTKDQG KKGPNKKLEK EQTGSKTLNG
481 GSDAQDGNQP QHNGESNEDS KDNHEASTKK KPSSEERETE ISLKDSTLDNLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PSIP1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.57
- Highest tissue expression
- 143 nTPM
Expression across tissuesHPA
Tissue
- retina: 143 nTPM
- cerebellum: 127 nTPM
- thymus: 121 nTPM
- cerebral cortex: 95 nTPM
- basal ganglia: 89 nTPM
- hypothalamus: 86 nTPM
Single-cell type
- late primary spermatocytes: 340 nCPM
- undifferentiated spermatogonia: 325 nCPM
- differentiating spermatogonia: 251 nCPM
- erythrocyte progenitors: 245 nCPM
- rod photoreceptor cells: 237 nCPM
- cardiomyocytes: 219 nCPM
Immune cell
- naive CD4 T-cell: 19 nTPM
- naive B-cell: 18 nTPM
- basophil: 14 nTPM
- T-reg: 13 nTPM
- memory CD4 T-cell: 13 nTPM
- naive CD8 T-cell: 12 nTPM
Brain region
- cerebral cortex: 135 nTPM
- cerebellum: 126 nTPM
- hypothalamus: 116 nTPM
- basal ganglia: 101 nTPM
- white matter: 100 nTPM
- midbrain: 92 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PSIP1.
Disease | ImmuneIEDB
Conditions an epitope on PSIP1 was assayed in.
- allergic disease B cell
Disease | AutoantibodyPubMed
Conditions in which antibodies against PSIP1 are reported. Each links to that disease's full target list.
Showing 2 of 3 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for PSIP1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
103 publications
- Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases.
2012 · J Rheumatol · RCR 4.3 · 115 citations - Anti-DFS70 antibodies in 597 healthy hospital workers.
2004 · Arthritis Rheum · RCR 4.3 · 162 citations - Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions.
2000 · J Allergy Clin Immunol · RCR 4.1 · 175 citations - The Clinical Relevance of Anti-DFS70 Autoantibodies.
2017 · Clin Rev Allergy Immunol · RCR 3.7 · 82 citations - Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases.
2012 · Autoimmun Rev · RCR 3.1 · 81 citations
Show 20 more of 103 total
- Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey.
2016 · Auto Immun Highlights · RCR 3 · 54 citations - The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases.
2012 · Clin Dev Immunol · RCR 2.9 · 72 citations - Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness.
2019 · Expert Rev Clin Immunol · RCR 2.8 · 54 citations - Clinical and serological features of patients referred through a rheumatology triage system because of positive antinuclear antibodies.
2014 · PLoS One · RCR 2.7 · 62 citations - Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort.
2013 · Clin Dev Immunol · RCR 2.6 · 64 citations - High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease.
2008 · Lupus · RCR 2.4 · 75 citations - Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases.
2018 · Clin Exp Rheumatol · RCR 2.2 · 38 citations - Towards a better understanding of the clinical association of anti-DFS70 autoantibodies.
2016 · Autoimmun Rev · RCR 2.1 · 46 citations - The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.
2017 · Lupus · RCR 1.9 · 42 citations - Recognition and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear Autoantibodies Testing at a Community Hospital.
2018 · Front Med (Lausanne) · RCR 1.9 · 31 citations - Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective.
2016 · Auto Immun Highlights · RCR 1.8 · 34 citations - Specific chemoluminescence and immunoasdorption tests for anti-DFS70 antibodies avoid false positive results by indirect immunofluorescence.
2015 · Clin Chim Acta · RCR 1.7 · 34 citations - DFS70 Autoantibodies: Clinical Utility in Antinuclear Antibody Testing.
2024 · Clin Chem · RCR 1.7 · 6 citations - Autoantibodies Against DFS70/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD).
2016 · Clin Lab · RCR 1.6 · 32 citations - Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern.
2016 · J Immunol Methods · RCR 1.6 · 29 citations - Anti-dense fine speckled 70 (DFS70) autoantibodies: correlates and increasing prevalence in the United States.
2023 · Front Immunol · RCR 1.5 · 8 citations - Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls.
2015 · J Rheumatol · RCR 1.4 · 27 citations - Clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing.
2020 · J Immunol Methods · RCR 1.4 · 16 citations - Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate.
2017 · Auto Immun Highlights · RCR 1.3 · 23 citations - Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience.
2019 · Clin Chem Lab Med · RCR 1.3 · 20 citations
Reference: B cellIEDB
1 publication
- Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain.
2004 · J Autoimmun · RCR 1.1 · 46 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.27
- gnomAD pLI
- 1
- gnomAD missense Z
- 0.11
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- chromatin remodeling
- mRNA 5'-splice site recognition
- positive regulation of transcription by RNA polymerase II
- response to heat
- response to oxidative stress
Molecular functions
- chromatin binding
- DNA-binding transcription factor binding
- RNA binding
- supercoiled DNA binding
- transcription coactivator activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PSIP1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PSIP1 as an antibody target. Whether an autoantibody or antibody against PSIP1 could matter depends on whether native PSIP1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PSIP1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PSIP1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...